These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 32754748

  • 1. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S.
    J Clin Endocrinol Metab; 2020 Sep 01; 105(9):. PubMed ID: 32754748
    [Abstract] [Full Text] [Related]

  • 2. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
    Brue T, Chanson P, Rodien P, Delemer B, Drui D, Marié L, Juban L, Salvi L, Henocque R, Raverot G.
    Front Endocrinol (Lausanne); 2021 Sep 01; 12():745843. PubMed ID: 34690933
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ.
    Lancet; 2021 Sep 01; 365(9471):1644-6. PubMed ID: 15885297
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
    Madsen M, Poulsen PL, Orskov H, Møller N, Jørgensen JO.
    J Clin Endocrinol Metab; 2011 Aug 01; 96(8):2405-13. PubMed ID: 21632808
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, Neggers SJCMM.
    J Clin Endocrinol Metab; 2018 Feb 01; 103(2):586-595. PubMed ID: 29155991
    [Abstract] [Full Text] [Related]

  • 7. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations.
    Gilroy JJ, James RA.
    Treat Endocrinol; 2002 Feb 01; 1(3):149-54. PubMed ID: 15799207
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
    Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P, Maffezzoni F, Montini M, Terzolo M, Ghigo E.
    J Clin Endocrinol Metab; 2017 Jul 01; 102(7):2454-2464. PubMed ID: 28419317
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
    Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML.
    J Clin Endocrinol Metab; 2005 Oct 01; 90(10):5684-91. PubMed ID: 16076947
    [Abstract] [Full Text] [Related]

  • 15. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.
    Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De Marinis L, Klibanski A.
    J Endocrinol Invest; 2009 Dec 01; 32(11):924-33. PubMed ID: 20009494
    [Abstract] [Full Text] [Related]

  • 16. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
    Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ.
    Pituitary; 2011 Sep 01; 14(3):253-8. PubMed ID: 21221818
    [Abstract] [Full Text] [Related]

  • 17. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug 01; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
    van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P.
    Eur J Endocrinol; 2011 Mar 01; 164(3):325-33. PubMed ID: 21148630
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.